Gilead Sciences Inc annual ebitda for fiscal TTM was $1.1 billion, a decrease of 91.9% from $13.6 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $1.1B | $13.6B | $4.4B | $7.6B | $8.9B | $11.3B | $4.1B | $7.6B | $10.3B | $15.9B | $19.2B | $23.4B | $16.3B | $4.9B | $4.3B | $4.2B | $4.3B | $3.8B | $2.9B | $2.2B | $1.7B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | ($10.0B) | $3.5B | $3.0B | $4.6B | $3.4B | $2.6B | $3.1B | $1.9B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More GILD metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All GILD financial statements → Interactive GILD charts →
About TickerBase · Data methodology & sources · Privacy · Terms